Abstract: The present invention provides a composite intelligent biological phototherapy device including a base structure, a plurality of white light fluorescent tubes arranged side by side on the base structure, a plurality of LEDs disposed between the white light fluorescent tubes, a housing having an opening and configured to accommodate the base structure and the white light fluorescent tubes and the LEDs thereon, a light-transmittable plate disposed on the housing corresponding to the opening, and an control module configured to respectively control the white light fluorescent tubes and the LEDs. The base structure includes a plurality of sections, and each of the sections has a first surface facing the light-transmittable plate. The white light fluorescent tubes and the LEDs are provided on the first surfaces, and the sections are bent relative to each other so an angle between the first surfaces of adjacent sections is less than 180 degrees.

Abstract: An automatic injection device is provided herein comprising a container body having a distal end and a proximal end; a piston locked at said proximal end of said container body before medication injection; a spring configured to bias said piston distally; a releasable restraining means configured to releasably restrain said piston in a locked state against said biasing of said spring, wherein, upon release of said releasable restraining means, said piston moves under force of said spring toward said distal end of said container body; an activation means configured to release said releasable means; a needle cap placed at said distal end of said container body; and a needle placed at said distal end of said container body.

Abstract: A method for treating autoimmune and/or inflammatory disease includes a step of identifying a subject exhibiting symptoms of autoimmune and/or inflammatory disease administering a fasting mimicking diet. A probiotic composition for gastrointestinal autoimmune and/or inflammatory disease Bacteroides acidifaciens, Bifidobacterium choerinum, and combinations thereof is also provided.

Abstract: An Ethernet transmission line includes two RJ45 connectors and a thin connection line. Each RJ45 connector has a connection terminal group, and the connection terminal group includes a first terminal, a second terminal, a third terminal, a fourth terminal, a fifth terminal, a sixth terminal, a seventh terminal, and an eighth terminal that are sequentially arranged. The thin connection line is connected between the two RJ45 connectors and the thin connection line includes a first flexible printed circuit board layer, a second flexible printed circuit board layer, and a spacing layer. The first flexible printed circuit board layer is provided with two first transmission lines respectively electrically connected to the third terminal and the sixth terminal. The second flexible printed circuit board layer is provided with two second transmission lines respectively electrically connected to the fourth terminal and the fifth terminal.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: A method of treating Alzheimer's associated pathology includes a step of identifying subject having a pathology that is associated with Alzheimer's disease. A fasting mimicking diet (FMD) is then administered to the subject for a first time period. Methods for treating amyloid plaque formation and/or elevated levels of tau protein as well as neuroinflammation are also provided.

Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.

Abstract: A pre-filled syringe for sterile medication fluid injection includes a syringe barrel with rotationally symmetric cylindrical bore, having a distal end and a proximal end; a syringe piston with rotationally symmetric external shape; a backstop mounted at the proximal end of the syringe barrel with an opening that is rotationally asymmetric about the axis through the syringe barrel; a push rod to move the syringe piston inside the syringe barrel, wherein at least one portion of the push rod is rotationally asymmetric about the axis through the syringe barrel, and upon rotation, the rotationally asymmetric portion of the push rod is aligned with the rotationally asymmetric opening of the backstop; and a seal component to cover the distal end of the syringe barrel.

Abstract: An Ethernet transmission line includes two RJ45 connectors and a thin connection line. Each RJ45 connector has a connection terminal group, and the connection terminal group includes a first terminal, a second terminal, a third terminal, a fourth terminal, a fifth terminal, a sixth terminal, a seventh terminal, and an eighth terminal that are sequentially arranged. The thin connection line is connected between the two RJ45 connectors and the thin connection line includes a first flexible printed circuit board layer, a second flexible printed circuit board layer, and a spacing layer. The first flexible printed circuit board layer is provided with two first transmission lines respectively electrically connected to the third terminal and the sixth terminal. The second flexible printed circuit board layer is provided with two second transmission lines respectively electrically connected to the fourth terminal and the fifth terminal.

Abstract: The method set out herein involves conducting adaptive clinical trial to develop parenteral therapeutic product with variable dose drug delivery devices. The method comprises using a variable dose drug delivery device to respond modifications during the adaptive clinical trial, wherein the variable dose drug delivery device is able to deliver more than one dose level and is for delivering fluid formulation. Other methods set out herein involve using a variable dose drug delivery device equipped with radio frequency identification (RFID) or near field communication (NFC) technology to improve patient adherence to drug administration in the adaptive clinical trial.

Abstract: A drug delivery device comprises a medication container containing medication for delivery and a detachable unit having an electronic circuit with a microprocessor. The electronic circuit is open and non-operational when the detachable component is assembled on the drug delivery device; and the electronic circuit is closed and operational when the detachable component is detached from the drug delivery device. The detachment of the detachable unit is an essential step to operate the drug delivery device. The detachable unit can be an activation protection cap or a needle shield remover for an autoinjector device. Alternatively, the detachable unit can be a needle shield remover for a pre-filled syringe.

Abstract: A medication injection device comprising a medication container to contain medication; a connector provided with a blocking feature; a push rod having a plurality of teeth disposed along the length, and a spring biasing against the push rod to move proximally. The spring can be compression spring, extension spring, torsion spring, or constant force spring. By enabling or disabling engagement between the blocking feature on the connector and the tooth on the push rod, the push rod is either prevented from moving distally or allowed to move distally. The medication is drawn into the medication container when the push rod moves proximally and the medication is dispensed out of the medication container when the push rod moves distally.

Abstract: A network sharing system includes an outdoor wireless transceiver device, an indoor network sharing device, and a high-speed Ethernet transmission cable. The outdoor wireless transceiver device includes a high-frequency network transceiver module and a first Ethernet port and the high-frequency network transceiver module is connected to the first Ethernet port and is configured to receive a high-frequency network signal. The indoor network sharing device includes a processing module and a second Ethernet port. The high-speed Ethernet transmission cable has a transmission rate above 1 giga bits per second (Gbps), two ends of the high-speed Ethernet transmission cable are respectively connected to a first RJ45 connector and a second RJ45 connector, the high-speed Ethernet transmission cable is provided with a flat cable segment, the first RJ45 connector is connected to the first Ethernet port, and the second RJ45 connector is connected to the second Ethernet port.

Abstract: A manufacturing method of a porous biomedical implant includes the steps of providing a supporter having a bearing surface, forming the porous biomedical implant on the bearing surface by additive manufacturing and removing the supporter after additive manufacturing. The porous biomedical implant includes a solid part and a porous part, the solid part is coupled to the bearing surface of the supporter and the porous part is coupled to the solid part. Particularly, the solid and porous parts are created in same layers by additive manufacturing.

Abstract: A mechanical device for assisting medication injection is provided herein comprising a connector having a distal end and a proximal end; a piston rod locked in said connector before medication injection; a spring configured to bias said piston rod distally; a releasable restraining means configured to releasably restrain said piston rod in a locked state against said biasing of said spring, wherein, upon release of said releasable restraining means, said piston rod moves distally under force of said spring; an activation means configured to release said releasable restraining means; and a mounting means for mounting a syringe at said distal end of said connector.

Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and/or radiation therapy. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7, 8, 9, 10, 10a, 11-hexahydro-5, 6, 7a, 11-tetraazacyclohepta [def] cyclopenta [a] fluoren-4 (5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and the use thereof.

Abstract: An electric actuator includes a motor having a rotary shaft. The electric actuator further includes a vibration damping gasket mounted on the motor. The vibration damping gasket includes an annular body attached around the motor and an end wall formed on one end of the annular body, and the end wall defines a through hole allowing the rotary shaft to pass therethrough. The motor further includes an outer housing, and the annular body of the vibration damping gasket is attached around the outer housing. The end wall of the vibration damping gasket contacts with the end surface of the outer housing. The vibration damping gasket is made from a resilient material. The electric actuator can effectively reduce the mechanical vibration, improve a buffering effect thereof, and hence reduce the noise.

Abstract: A medication delivery device, for use with a container having a distal end and a needle being placed at the distal end of the container, including: a push rod which is movable with respect to at least a portion of the container; a resilient member configured to bias the push rod to move toward the distal end of the container; a releasable restraining means configured to releasably restrain the push rod in a locked state against the biasing of the resilient member; a means to adjust amount of movement of the push rod with respect to the container in order to deliver a predetermined dose of medication; and an activation means configured to release the releasable means. The means to adjust amount of movement of the push rod with respect to the container is bi-directional. The device can accommodate containers of different size or shape.

Abstract: An apparatus, method and computer-readable medium provide control of set top box volume based on mobile device events. The apparatus may execute a process that includes controlling a volume setting of an audio amplifier to output audio content to the one or more audio or audio/visual devices. A connection event signal from a mobile device is received via a wireless radio frequency receiver. The connection event signal indicates a call state of the mobile device. In response to receiving the connection event signal, a received signal strength indication associated with the connection event signal obtained. A volume setting that corresponds to the obtained received signal strength indication is determined. The volume setting output to the audio amplifier is adjusted according to the determined volume setting.